Pokima N, Khattar G, Keesari P, Khan S, Asogwa N, Niazi M
Cureus. 2024; 16(5):e60161.
PMID: 38868249
PMC: 11166541.
DOI: 10.7759/cureus.60161.
Lubke J, Christen D, Schwaab J, Kaiser A, Naumann N, Shoumariyeh K
Leukemia. 2024; 38(4):810-821.
PMID: 38448757
PMC: 10997505.
DOI: 10.1038/s41375-024-02186-x.
Valent P, Akin C, Arock M, Gleixner K, Greinix H, Hermine O
Int J Mol Sci. 2023; 24(20).
PMID: 37894806
PMC: 10607143.
DOI: 10.3390/ijms242015125.
Chang L, Zhang L, Zhang Y, Feng J, Zhou D, Cao X
Zhonghua Xue Ye Xue Za Zhi. 2023; 44(4):336-339.
PMID: 37357005
PMC: 10282877.
DOI: 10.3760/cma.j.issn.0253-2727.2023.04.013.
Lubke J, Naumann N, Metzgeroth G, Kreil S, Brand T, Horny H
Ann Hematol. 2023; 102(8):2077-2085.
PMID: 37012462
PMC: 10344834.
DOI: 10.1007/s00277-023-05180-y.
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms.
Gotlib J
Hematology Am Soc Hematol Educ Program. 2022; 2022(1):34-46.
PMID: 36485158
PMC: 9821059.
DOI: 10.1182/hematology.2022000368.
Treatment of Advanced Systemic Mastocytosis with Midostaurin: Practical Guidance for Optimal Therapy and Management.
Papayannidis C, Federico V, Fianchi L, Pregno P, Pugliese N, Romano A
Mediterr J Hematol Infect Dis. 2022; 14(1):e2022073.
PMID: 36425146
PMC: 9652003.
DOI: 10.4084/MJHID.2022.073.
Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.
El Hussein S, Chifotides H, Khoury J, Verstovsek S, Thakral B
Cancers (Basel). 2022; 14(14).
PMID: 35884535
PMC: 9322501.
DOI: 10.3390/cancers14143474.
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis.
Reiter A, Gotlib J, Alvarez-Twose I, Radia D, Lubke J, Bobbili P
Leukemia. 2022; 36(8):2108-2120.
PMID: 35790816
PMC: 9343245.
DOI: 10.1038/s41375-022-01615-z.
Target Therapies for Systemic Mastocytosis: An Update.
Sciume M, De Magistris C, Galli N, Ferretti E, Milesi G, De Roberto P
Pharmaceuticals (Basel). 2022; 15(6).
PMID: 35745657
PMC: 9229771.
DOI: 10.3390/ph15060738.
Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel.
Velloso E, Padulla G, Cerqueira A, Sousa A, Sandes A, Traina F
Hematol Transfus Cell Ther. 2022; 44(4):582-594.
PMID: 35688791
PMC: 9605912.
DOI: 10.1016/j.htct.2022.04.006.
Precision Medicine in Systemic Mastocytosis.
Nicolosi M, Patriarca A, Andorno A, Mahmoud A, Gennari A, Boldorini R
Medicina (Kaunas). 2021; 57(11).
PMID: 34833353
PMC: 8623914.
DOI: 10.3390/medicina57111135.
Systemic Mastocytosis: Molecular Landscape and Implications for Treatment.
Monaldi C, De Santis S, Mancini M, Bruno S, Cavo M, Soverini S
Mediterr J Hematol Infect Dis. 2021; 13(1):e2021046.
PMID: 34276915
PMC: 8265368.
DOI: 10.4084/MJHID.2021.046.
MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis.
Jawhar M, Schwaab J, Alvarez-Twose I, Shoumariyeh K, Naumann N, Lubke J
J Clin Oncol. 2019; 37(31):2846-2856.
PMID: 31509472
PMC: 6823885.
DOI: 10.1200/JCO.19.00640.
Clinical potential of midostaurin in advanced systemic mastocytosis.
Chandesris M, Damaj G, Lortholary O, Hermine O
Blood Lymphat Cancer. 2019; 7:25-35.
PMID: 31360083
PMC: 6467340.
DOI: 10.2147/BLCTT.S87186.
Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
Ungerstedt J
Int J Mol Sci. 2018; 19(10).
PMID: 30304859
PMC: 6212943.
DOI: 10.3390/ijms19103091.
Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
Baird J, Gotlib J
Curr Hematol Malig Rep. 2018; 13(5):407-416.
PMID: 30155614
DOI: 10.1007/s11899-018-0469-3.
Preclinical human models and emerging therapeutics for advanced systemic mastocytosis.
Arock M, Wedeh G, Hoermann G, Bibi S, Akin C, Peter B
Haematologica. 2018; 103(11):1760-1771.
PMID: 29976735
PMC: 6278969.
DOI: 10.3324/haematol.2018.195867.
D816V Positive Acute Mast Cell Leukemia Associated with Normal Karyotype Acute Myeloid Leukemia.
Lopes M, Teixeira M, Casais C, Mesquita V, Seabra P, Cabral R
Case Rep Hematol. 2018; 2018:3890361.
PMID: 29670776
PMC: 5835284.
DOI: 10.1155/2018/3890361.
Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Gallogly M, Lazarus H, Cooper B
Ther Adv Hematol. 2017; 8(9):245-261.
PMID: 29051803
PMC: 5639976.
DOI: 10.1177/2040620717721459.
